Form 4: Kairos Pharma CFO Granted 152,672 Restricted Stock Units

Kairos Pharma's Chief Financial Officer, Doug Samuelson, was granted 152,672 restricted stock units under the company's 2023 Equity Incentive Plan.

Summary

• Doug Samuelson, Chief Financial Officer of Kairos Pharma, LTD. (KAPA), was granted 152,672 restricted stock units (RSUs).
• The RSUs were issued under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan.
• The grant date for these RSUs was October 8, 2025.
• These RSUs are scheduled to vest in full on the first anniversary of the grant date, which is October 8, 2026.
• Following this transaction, Mr. Samuelson beneficially owns 293,039 securities, comprising 140,367 shares of common stock and the 152,672 unvested RSUs.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (RSU grant), which is generally positive for executive alignment but neutral in terms of immediate operational impact. It's a routine disclosure without significant positive or negative surprises.

Positives

• The grant of restricted stock units aligns the interests of the Chief Financial Officer, Doug Samuelson, with those of shareholders, as the value of the RSUs is tied to the company's stock performance.
• Equity incentive plans are a common and effective way to attract, retain, and motivate key executives.

Negatives

• The future vesting of these RSUs will result in a slight dilution of existing shareholder equity, although this is a standard practice for executive compensation.

Future Outlook

The 152,672 restricted stock units granted to the CFO are scheduled to vest in full on October 8, 2026, indicating a future milestone for this compensation.

Industry Context

The use of restricted stock units as executive compensation is a standard practice across various industries, including the pharmaceutical sector, to incentivize long-term performance and retention.

Comparison to Industry Standards

• The grant of RSUs to a Chief Financial Officer is a common form of executive compensation, aligning with practices seen in comparable biotech and pharmaceutical companies.
• The vesting schedule, a one-year cliff vest, is within the typical range for such grants, though multi-year vesting is also common.
• The size of the grant (152,672 RSUs) would need to be evaluated against the company's market capitalization and the executive's overall compensation package to assess its competitiveness and alignment with peer group practices, but this filing alone does not provide enough data for a detailed comparison.

Related Party Transactions

• The grant of RSUs to the Chief Financial Officer is a transaction between the company and a related party (executive management), which is disclosed as part of executive compensation.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting, but improved executive alignment and retention.
• Employees: May signal a stable compensation strategy and commitment to executive talent.
• Management: Increased equity stake and long-term incentive.

Next Steps

• The 152,672 restricted stock units are scheduled to vest in full on October 8, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and does not provide new information that would fundamentally alter the investment thesis for Kairos Pharma. While it indicates continued executive alignment, it's not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should 'hold' and consider this information in the broader context of the company's financial performance, strategic developments, and market conditions.

Keywords

Kairos Pharma, KAPA, Doug Samuelson, CFO, Restricted Stock Units, RSU, Equity Incentive Plan, Executive Compensation, Insider Transaction, Form 4, Beneficial Ownership